Uni-Bio Science Group (Stock Code: 0690), established in 2001, is a leading Chinese biopharmaceutical healthcare company focusing on the four strategic areas of bio-innovative drugs, high-value generic drugs, medical cosmetology, and CMO, integrating R&D, production and sales.
Uni-Bio Science is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions. China’s well-documented chronic diseases, ageing population and growing population places great strain on our healthcare systems, however Uni-Bio Science has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function.
Uni-Bio Science is committed to improving the quality of life of patients through innovative therapies and is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions. China’s well-documented chronic diseases, ageing population and growing population places great strain on our healthcare systems, however Uni-Bio Science has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function, and has achieved several major milestones.
We have proactively bolstered our operational capabilities to continue the strong momentum we have achieved: establishing new Medical and Market Access departments; and increasing both our field activities and share of voice.
Uni-Bio Science has established a strong track record in its approach to bolstering its product portfolio through strategic partnerships and in-licensing agreements. We have recently formed a strategic alliance with Heungkong Group, a top 50 PRC private enterprise on exploring promotion opportunities for Uni-Bio product in their healthcare networks as well as other initiatives. The alliance reassured the broad commercial and development expertise that we have nurtured within our organisation, combined with our commitment to operating ethically and responsibly, positions us as the partner of choice of many reputable healthcare companies and beyond. Our innovative business model ensures we will remain competitive and is enabling us to build a portfolio of world-class treatments and healthcare solutions for patients throughout China.
We have invested, and continue to invest, in ensuring we operate supply chains with utmost security and accountability, especially in good compliance to the latest distribution policy of PRC. Our manufacturing facilities throughout China have all been fitted with state-of the-art equipment and are cGMP approved, establishing the Group as the provider of choice in the provision of high-quality products.
With the strong foundation and good track records in the focused therapeutic domain, Uni-Bio will continue to strive to become a leader for chronic diseases management and provide innovative healthcare products and solution to the Nation.
